The role of trimethylation on histone H3 lysine 27 (H3K27me3) in temozolomide resistance of glioma
Brain Research · 2025
DOI: 10.1016/j.brainres.2024.149252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Research, 2025. Verfasst von Xiaopei Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sixth Department of Oncology, Hebei General Hospital, Shijiazhuang 050057, Hebei, China; Graduate School, Hebei North University, Zhangjiakou 075132,…. Hauptthemen laut MEDLINE: Temozolomide, Glioma, Drug Resistance, Neoplasm, Histones. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Jilin University, Natural Science Foundation of Hebei Province.
Abstract (Originalsprache)
Temozolomide (TMZ) is the first-line chemotherapeutic agent for malignant glioma, but its resistance limited the benefits of the treated patients. In this study, the role and significance of trimethylation of histone H3 lysine 27 (H3K27me3) in TMZ resistance were investigated. Data from twenty advanced glioma patients were collected, and their pathological samples were analyzed for H3K27me3 levels. TMZ sensitivity was compared between glioma cells U87 and TMZ-resistant cells U87TR, with H3K27me3 levels determined in both cells. The effects of H3K27me3 demethylases inhibitor GSK-J4, combined with TMZ, were assessed on the proliferation and migration of U87TR cells. The results indicated that a high level of H3K27me3 predicts longer disease free survival (DFS) and overall survival (OS) in glioma patients receiving TMZ treatment. The H3K27me3 level was lower in U87TR cells compared to U87 cells. GSK-J4 increased the H3K27me3 level in U87TR cells and decreased their resistance to TMZ. In summary, this study identified a novel marker of TMZ resistance in glioma and provided a new strategy to address this challenge. These findings are significant for improving the clinical treatment of glioma in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sixth Department of Oncology, Hebei General Hospital, Shijiazhuang 050057, Hebei, China; Graduate School, Hebei North University, Zhangjiakou 075132, Hebei, China.
- Sixth Department of Oncology, Hebei General Hospital, Shijiazhuang 050057, Hebei, China.
- Second Department of Neurosurgery, Hebei General Hospital, Shijiazhuang 050057, Hebei, China.
- Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China.
- Department of Sports Human Sciences, Hebei Sport University, Shijiazhuang 050041, Hebei, China. Electronic address: xiaoqiangguo123@163.com.
- Sixth Department of Oncology, Hebei General Hospital, Shijiazhuang 050057, Hebei, China. Electronic address: suiaxhebei@126.com.
Förderung
- Jilin University
- Natural Science Foundation of Hebei Province
Zitieren
APA
Zhang, X., Li, L., Li, Y., Dong, C., Shi, J., Guo, X., & Sui, A. (2025). The role of trimethylation on histone H3 lysine 27 (H3K27me3) in temozolomide resistance of glioma. Brain Research. https://doi.org/10.1016/j.brainres.2024.149252
Vancouver
Zhang X, Li L, Li Y, Dong C, Shi J, Guo X, et al. The role of trimethylation on histone H3 lysine 27 (H3K27me3) in temozolomide resistance of glioma. Brain Research. 2025. doi:10.1016/j.brainres.2024.149252
BibTeX
@article{Zhang2025,
author = {Zhang, Xiaopei and Li, Li and Li, Yitong and Dong, Changzheng and Shi, Jian and Guo, Xiaoqiang and Sui, Aixia},
title = {The role of trimethylation on histone H3 lysine 27 (H3K27me3) in temozolomide resistance of glioma},
journal = {Brain Research},
year = {2025},
doi = {10.1016/j.brainres.2024.149252}
}
EUVIMED